NewEdge Wealth LLC Acquires Shares of 4,186 Teleflex Incorporated $TFX

NewEdge Wealth LLC bought a new stake in Teleflex Incorporated (NYSE:TFX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,186 shares of the medical technology company’s stock, valued at approximately $531,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Empowered Funds LLC raised its position in Teleflex by 15.8% in the 1st quarter. Empowered Funds LLC now owns 1,684 shares of the medical technology company’s stock worth $233,000 after purchasing an additional 230 shares during the period. Jane Street Group LLC boosted its position in shares of Teleflex by 42.6% during the first quarter. Jane Street Group LLC now owns 6,343 shares of the medical technology company’s stock valued at $877,000 after buying an additional 1,895 shares during the period. American Century Companies Inc. boosted its position in shares of Teleflex by 32.7% during the second quarter. American Century Companies Inc. now owns 13,640 shares of the medical technology company’s stock valued at $1,614,000 after buying an additional 3,360 shares during the period. Invesco Ltd. grew its stake in shares of Teleflex by 1.2% during the second quarter. Invesco Ltd. now owns 135,516 shares of the medical technology company’s stock valued at $16,040,000 after buying an additional 1,659 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Teleflex by 108.1% during the second quarter. EverSource Wealth Advisors LLC now owns 1,003 shares of the medical technology company’s stock valued at $119,000 after buying an additional 521 shares during the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Stock Up 3.0%

Shares of NYSE:TFX opened at $138.99 on Friday. Teleflex Incorporated has a 52-week low of $100.18 and a 52-week high of $145.00. The stock has a market cap of $5.89 billion, a P/E ratio of -5.97, a price-to-earnings-growth ratio of 0.93 and a beta of 0.81. The business’s 50 day moving average is $132.70 and its 200 day moving average is $124.73. The company has a quick ratio of 2.12, a current ratio of 2.60 and a debt-to-equity ratio of 0.94.

Teleflex (NYSE:TFX) last issued its earnings results on Thursday, August 6th. The medical technology company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.48. Teleflex had a positive return on equity of 11.93% and a negative net margin of 39.67%.The business had revenue of $570.33 million during the quarter, compared to analyst estimates of $559.59 million. During the same period in the previous year, the company posted $3.73 EPS. Teleflex’s revenue was up 28.9% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. Sell-side analysts predict that Teleflex Incorporated will post 7.26 EPS for the current year.

Teleflex Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Friday, August 14th will be paid a $0.34 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $1.36 dividend on an annualized basis and a yield of 1.0%. Teleflex’s dividend payout ratio is -5.84%.

Analyst Upgrades and Downgrades

TFX has been the subject of a number of research analyst reports. Piper Sandler reissued an “overweight” rating and set a $169.00 price target (up from $160.00) on shares of Teleflex in a research note on Friday, August 7th. BMO Capital Markets initiated coverage on Teleflex in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $159.00 target price on the stock. Royal Bank Of Canada upgraded Teleflex from a “sector perform” rating to an “outperform” rating and lifted their target price for the stock from $135.00 to $155.00 in a research report on Friday, May 8th. Weiss Ratings reissued a “sell (d)” rating on shares of Teleflex in a research note on Wednesday, June 24th. Finally, Truist Financial boosted their target price on shares of Teleflex from $143.00 to $150.00 and gave the company a “hold” rating in a research note on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Teleflex has an average rating of “Hold” and an average price target of $151.80.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.